Lantheus (NASDAQ:LNTH) posted its quarterly earnings data on Thursday. The medical equipment provider reported $0.10 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.08, Briefing.com reports. Lantheus had a net margin of 3.51% and a return on equity of 20.57%. The firm had revenue of $66.01 million during the quarter, compared to analysts’ expectations of $55.77 million. During the same quarter last year, the company posted $0.27 EPS. The company’s quarterly revenue was down 23.0% compared to the same quarter last year.
Shares of LNTH stock traded down $1.17 during trading hours on Friday, reaching $13.48. The company had a trading volume of 1,600,707 shares, compared to its average volume of 578,579. The company has a 50 day moving average of $14.59 and a 200 day moving average of $14.48. The company has a debt-to-equity ratio of 0.41, a current ratio of 2.37 and a quick ratio of 2.41. The firm has a market cap of $535.97 million, a price-to-earnings ratio of 44.93 and a beta of 1.26. Lantheus has a 1-year low of $8.67 and a 1-year high of $27.12.
Several research analysts have issued reports on the company. Zacks Investment Research raised Lantheus from a “sell” rating to a “hold” rating in a report on Friday, July 10th. Jefferies Financial Group assumed coverage on Lantheus in a report on Monday, June 29th. They set a “buy” rating and a $29.00 price objective on the stock. CJS Securities raised Lantheus from a “market perform” rating to an “outperform” rating in a report on Tuesday, June 16th. Finally, BidaskClub raised Lantheus from a “sell” rating to a “hold” rating in a report on Tuesday, June 23rd. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average target price of $29.00.
Lantheus Company Profile
Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases worldwide. Its principal products include DEFINITY, a microbubble contrast agent used in ultrasound exams of the heart; and TechneLite, a technetium generator that provides the nuclear material used in nuclear medicine procedures.
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.